A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides
eLife · 2024
DOI: 10.7554/elife.96190 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Malik Zohaib Ali und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Colorado State University, Fort Collins, United States. Hauptthemen laut MEDLINE: Antitubercular Agents, Linezolid, Mice, Inbred BALB C, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORIP NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The Nix-TB clinical trial evaluated a new 6 month regimen containing three oral drugs; bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL regimen) for the treatment of tuberculosis (TB). This regimen achieved remarkable results as almost 90% of the multidrug-resistant or extensively drug-resistant TB participants were cured but many patients also developed severe adverse events (AEs). The AEs were associated with the long-term administration of the protein synthesis inhibitor linezolid. Spectinamide 1599 is also a protein synthesis inhibitor of Mycobacterium tuberculosis with an excellent safety profile, but it lacks oral bioavailability. Here, we propose to replace L in the BPaL regimen with spectinamide (S) administered via inhalation and we demonstrate that inhaled spectinamide 1599, combined with BPa ––BPaS regimen––has similar efficacy to that of the BPaL regimen while simultaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effects in both TB murine models. However, treatment with BPaL resulted in significant weight loss and the complete blood count suggested the development of anemia. These effects were not similarly observed in mice treated with BPaS. BPaL and BPa, but not the BPaS treatment, also decreased myeloid to erythroid ratio suggesting the S in the BPaS regimen was able to recover this effect. Moreover, the BPaL also increased concentration of proinflammatory cytokines in bone marrow compared to mice receiving BPaS regimen. These combined data suggest that inhaled spectinamide 1599 combined with BPa is an effective TB regimen without L-associated AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mycobacteria Research Laboratories, Colorado State University, Fort Collins, United States.
- Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, United States.
- Program in Cell & Molecular Biology, Colorado State University, Fort Collins, United States.
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, United States.
- Technology Advancement and Commercialization, RTI International, Research Triangle Park, United States.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, United States.
ORCID-Profile: Malik Zohaib Ali, Mercedes Gonzalez Juarrero
Förderung
- ORIP NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Fulbright U.S. Student Program
- NIH HHS
- Office of Research Infrastructure Programs
Zitieren
APA
Zohaib Ali, M., Dutt, T. S., MacNeill, A., Walz, A., Pearce, C., Lam, H., Philp, J. S., Patterson, J., Henao-Tamayo, M., Lee, R., Liu, J., Robertson, G. T., Hickey, A. J., Meibohm, B., & Gonzalez Juarrero, M. (2024). A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. eLife. https://doi.org/10.7554/elife.96190
Vancouver
Zohaib Ali M, Dutt TS, MacNeill A, Walz A, Pearce C, Lam H, et al. A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. eLife. 2024. doi:10.7554/elife.96190
BibTeX
@article{ZohaibAli2024,
author = {Zohaib Ali, Malik and Dutt, Taru S and MacNeill, Amy and Walz, Amanda and Pearce, Camron and Lam, Ha and Philp, Jamie S and Patterson, Johnathan and Henao-Tamayo, Marcela and Lee, Richard and Liu, Jiuyu and Robertson, Gregory T and Hickey, Anthony J and Meibohm, Bernd and Gonzalez Juarrero, Mercedes},
title = {A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.96190}
}
EUVIMED